affinized, rehydrated, and incubated in 0.4% pepsin in 0.2 n HCl at 22°C for 7 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide at 22°C for 15 A patient with low-grade lymphoma presented 8 months after autologous marrow transplantation with dizziness, min followed by air drying. JC virus DNA probe (Enzo Diagnostics, Farmingdale, NY, USA) in a stringent aphasia and hemiparesis. Magnetic resonance imaging (MRI) showed an abnormal T2 signal in the frontoparhybridization mixture was applied, and the slides were coverslipped. Following denaturation at 95°C for 15 min, ietal region unilaterally. Biopsy of the area demonstrated progressive multifocal leukoencephalopathy the slides were hybridized overnight at 37°C in a humidified chamber. Slides were then washed in 4 × saline sodium positive for JC virus and p53. Treatment with interleukin-2 at 0.5 MU/m 2 /day i.v. continuous infusion resulted citrate (SSC) at 22°C three times, then stringently in 0.1 × SSC at 60°C twice. Detection was accomplished using the in near complete resolution of symptoms and MRI abnormalities. The absolute number of CD3 + CD4 + and ABC Elite kit (Vector Laboratories, Burlingame, CA, USA) with 3-amino-9-ethylcarbazole as the chromagen and CD3 − CD56 + cells in the peripheral blood also increased, and the CD4/CD8 ratio normalized. She remains free of Mayer's hematoxylin as the counterstain. evidence of progressive multifocal leukoencephalopathy 1 year off therapy. p53 immunohistochemistry Keywords: progressive multifocal leukoencephalopathy; treatment; interleukin-2; JC virus Four m thick sections from formalin-fixed paraffinembedded tissue were deparaffinized, rehydrated, and boiled in a microwave oven for 10 min. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide Progressive multifocal leukoencephalopathy (PML) is a in absolute methanol, followed by treatment with 1% acetic subacute demyelinating disorder caused by infection of acid in phosphate-buffered saline (PBS) for 5 min to block glial cells with JC virus, a neurotropic polyomavirus. JC endogenous alkaline phosphatase. Nonspecific background viral infections occur in less than 10% of marrow transplant binding was blocked by incubation with normal goat serum patients.
In situ hybridization for JC virus
Quantitative immunophenotyping Tissue sections of 4 m thickness were prepared from forImmunophenotyping was performed by standard two-color malin-fixed paraffin-embedded tissue, and then were deparflow cytometry technique using monoclonal antibodies to CD3, CD4, CD8, CD19, CD56, CD45RA and CD45RO Pretreatment MRI revealed a large focal area of white matter abnormality involving the deep fronto-parietal lobe (large arrows) and the subcortical U-fibers (small arrows) (a). MRI during therapy showed near complete resolution of the white matter abnormalities (black arrows), although a collection of blood at the site of the stereotactic biopsy remains (white arrow) (b). MRI 1 year off therapy shows complete resolution of the white matter abnormalities (c).
age of cells of each subset in the gated region was determined by setting the quadrants visually above the background of the isotype control. Results are reported for subsets that are CD3
The absolute number of each subset was calculated by multiplying the percentage of the gated region by the absolute lymphocyte count.
Case report
A 46-year-old female received high-dose etoposide, cyclophosphamide, total-body irradiation, and autologous marrow and blood stem cells as treatment for responsive first relapse of low-grade lymphoma. Her early post-transplant course was remarkable only for cytomegalovirus pneumonia that responded to ganciclovir and intravenous immunoglobulin. Six months after transplantation, she was still thrombocytopenic and lymphopenic.
Eight months post-transplant the patient presented with . JC virus T antigen is thought to stabilize p53 antigen and result in its accumulation. 5 This allows for detection of p53 by immunohistochemistry in productively infected cells as was demonstrated in the biopsy from this patient (Figure 2) .
The patient was unable to receive cytarabine or interferon because of low blood counts. The neutrophil count was 1.794 × 10 9 /l, lymphocyte count 0.676 × 10 9 /l, platelet count 61 × 10 9 /l, CD3 − CD56 + cell count 0.063 × 10 9 /l, CD3 + CD4 + count 0.149 × 10 9 /l, CD4/CD8 ratio 0.360, and the ratio of CD4
Cetus, Emeryville, CA, USA) 0.5 MU/m 2 /day i.v. was given by continuous infusion for a 4-week course. There was improvement in the speech and motor function which worsened again when off IL-2 for 1 week. Treatment with IL-2 was resumed, and there was progressive resolution of symptoms as well as partial resolution of the MRI abnormalities (Figure 1 ). At 4 months of therapy, she began to develop low-grade fever, easy fatigue, malaise, arthralgias and eosinophilia. IL-2 was discontinued when the constitutional symptoms became intolerable after a total of 6.5 months of therapy, 2 months after initial maximal improvement of the MRI.
During treatment with IL-2, the neutrophil count rose, and the lymphocyte count fell (Figure 3 ). However, there was slow but progressive improvement in the CD4/CD8 ratio and RA/RO ratio. The day after IL-2 was stopped, there was a transient rebound lymphocytosis comprised of T and NK cells. At 8 months off treatment, the neutrophil b count was 3.468 × 10 9 /l, lymphocyte count 1.066 × 10 9 /l, platelet count 165 × 10 9 /l, CD3 − CD56 + cell count 0.074 × 10 9 /l, CD3 + CD4 + cell count 0.364 × 10 9 /l, CD4/CD8 ratio 0.683, and RA/RO ratio 1.122. At one year off IL-2, the patient has no evidence of recurrence of PML.
Discussion
A deficiency in cell-mediated immunity and increased risk of opportunistic infections after autologous marrow or blood stem cell transplantation have been well-characterized. Cayeux et al 6 reported that this immunodeficient state is due in part to a defect in IL-2 production posttransplant. Since the in vitro manifestations of the immunodeficiency after autologous transplantation can be reversed by administration of low doses of IL-2 without substantial toxicity, [7] [8] [9] we chose to use continuous-infusion low-dose IL-2 for our patient with PML. Treatment was tolerated for c 6 months and resulted in a sustained remission of the disease. Although there are rare reports of spontaneous being such a case.
How treatment with IL-2 effected resolution of PML in our patient is unclear. While IL-2 is known to increase MHC-nonrestricted cytotoxic activity against virus-infected cells, such a process might conceivably lead to excessive tissue destruction and worsening of the neurologic symptoms. More recently, Chang et al 10 showed that activated T cell supernatant reinduced JC viral latency in glial cells in vitro. Activated T cell supernatant as well as purified interferon-␥ and tumor necrosis factor-␣ also induced a transacting protein in glial cells that binds to the viral origin of replication. Since IL-2 treatment stimulates production of these cytokines in vivo, 11 soluble factors produced by IL-2-activated T cells may be responsible for the control of PML seen in our patient. Whether IL-2 can reinduce latency of other viruses by this mechanism is clearly worthy of further investigation. 
